CD8+T-cell counts: an early predictor of risk and mortality in critically ill immunocompromised patients with invasive pulmonary aspergillosis

Table 2 Clinical characteristics of critically ill immunocompromised patients ^a

Variables	All patients (n = 150)	No IPA (n = 88, 58.7%)	IPA (n = 62, 41.3%)	No IPA vs IPA Pvalue
Life-sustaining treatments,^bn (%)
Need for mechanical ventilation	126 (84.0)	69 (78.4)	57 (91.9)	0.036
Need for vasopressor	122 (81.3)	66 (75.0)	56 (90.3)	0.020
Need for RRT	38 (25.3)	24 (27.3)	14 (22.6)	0.571
Indwelling catheter,^cn (%)
Urinary catheter	146 (97.3)	85 (96.6)	61 (98.4)	0.643
CVC	141 (94.0)	81 (92.0)	60 (96.8)	0.308
Drug therapy,^dn (%)
Antifungal drugs	117 (78.0)	63 (71.6)	54 (87.1)	0.028
Corticosteroids^e	105 (70.0)	57 (64.8)	48 (77.4)	0.107
IVIG^f	43 (28.7)	20 (22.7)	23 (37.1)	0.067
Antibiotics for GNB^g	147 (98.0)	86 (97.7)	61 (98.4)	>0.999
Antibiotics for GPB	98 (65.3)	56 (63.6)	42 (67.7)	0.728
Antiviral drugs	73 (48.7)	37 (42.0)	36 (58.1)	0.068
TMP-SMX	55 (36.7)	29 (33.0)	26 (41.9)	0.303
Outcomes
ICU duration (days)	10.0 (11.0)	9.0 (10.0)	11.0 (14.0)	0.325
Hospital duration, (days)	29.0 (48.0)	30.0 (46.0)	27.0 (54.0)	0.681
ICU mortality, n (%)	64 (42.7)	29 (33.0)	35 (56.5)	0.005
Hospital mortality, n (%)	78 (52.0)	37 (42.0)	41 (66.1)	0.005
28-day mortality, n (%)	72 (48.0)	34 (38.6)	38 (61.3)	0.008
60-day mortality, n (%)	80 (53.3)	40 (45.5)	40 (64.5)	0.030
90-day mortality, n (%)	96 (64.0)	46 (52.3)	50 (80.6)	<0.001

^aCVC central venous catheter, GNB Gram-negative bacilli, GPB Gram-positive bacteria, IPA invasive pulmonary aspergillosis, IVIG intravenous immunoglobulin, RRT renal replacement therapy, TMP-SMX trimethoprim/sulfamethoxazole. Continuous variables are expressed as the means ± SD or medians (IQR). All other data are raw numbers (%). ^bVariable defined as life-sustaining treatment for 24 hours or longer during the study. ^cVariable defined as the proportion of patients with catheter placed within the first 3 days following ICU admission. ^dVariable defined as systemic drug therapy for 48 hours or longer during the ICU stay. ^eCorticosteroid therapy was defined according to the 2008 EORTC-MSG criteria [6]: mean minimum dose of 0.3 mg/kg/day prednisone equivalent for more than 3 weeks during ICU stay. Other corticosteroids should be converted into equivalent dose of prednisone before calculation and comparison. ^fRoutine treatment was immunoglobulin 10 g/day. ^gVariable defined as all GNB except multi-drug-resistant bacteria.

ISSN: 1364-8535